IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	361
INN	enokizumab
INN Number	9262
INN Prop. List	104 (2010)
INN Rec. List	66 (2011)
Common name	7F3com-2H2, MEDI-528
Proprietary name
Species	Humanized
IMGT receptor type	IG
Format (legend)
Receptor identification	IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	9262
IMGT/3Dstructure-DB
Specificity target name and species	IL9 (interleukin 9, IL-9, T cell growth factor p40) [Humanized]
Development Technology
Origin clone species
Origin clone name

Company	MedImmune (Gaithersburg MD USA); AstraZeneca (London UK)
Expression system
Application	Therapeutic
Clinical domain	Immunology
Mechanism of action
Clinical indication	Asthma
Development status	Phase II
Regulatory agency status and year

Clinical trials
Authority decisions
External links	NCIt: C97929
IMGT notes	In 2007, AstraZeneca bought MedImmune created in 1988. On Feb 14, 2019, it was announced that MedImmune will cease to exist as an industry name as the owner AstraZenaca has decided to retire the brand as part of ongoing restructuring efforts.https://www.biopharmadive.com/news/astrazeneca-retires-medimmune-name-amid-sales-turnaround/548489/
IMGT references	Antoniu SA, et al., Curr. Opin. Mol. Ther. 2010; 12(2):233-9. PMID: 20373267
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation